While in nursing school, a patient recognized potential signs of a blood disorder and advocated for further testing, leading to an early diagnosis of essential thrombocythemia. Despite initial ...
Over the past 35 years, interferons have been explored in various formulations for the management of Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs), such as essential ...
Patients with essential thrombocythemia faced an average delay of 26.5 months between their first high platelet count and diagnosis. Patients experienced a significant delay in receiving an essential ...
WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) today announced the first clinical data from two studies evaluating the safety, tolerability and efficacy of INCA033989, a novel, first in ...
Verywell Health on MSN
What Are Myeloproliferative Disorders?
Myeloproliferative disorders include several different conditions that are characterized by excess production of blood cells ...
LOUISVILLE, Ky.--(BUSINESS WIRE)--Onco360 ®, the nation’s leading independent Specialty Pharmacy, has been selected as a pharmacy partner by GlaxoSmithKline for OJJAARA™ (momelotinib). OJJAARA is a ...
Hemorrhagic events post-diagnosis in patients with ET significantly increase mortality risk, more than thrombosis or disease progression. Intracranial hemorrhage is the most lethal bleeding ...
QRISK3 effectively predicts thrombotic risk in polycythemia vera and essential thrombocythemia, surpassing traditional risk assessments. High QRISK3 scores correlate with increased thrombotic events, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback